FORM D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

OMB Number: 3235-0076 Expires: May 31, 2002 Estimated average burden hours per form......1

OMB APPROVAL

NOTICE OF SALE OF SECURITIES 58 PURSUANT TO REGULATION B, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

SE	C USE ON	LY
Prefix		Serial
DA	ΓΕ RECEIV	/ED

Name of Offering (☐ check if this is an		anged, an	d indicate change.)				
Limited Partnership Interests of NeuroVe							
Filing Under (Check box(es) that apply):	Rule 50	4	Rule 505	⊠ Rule 506	☐ Section 4	4(6) 🔲 ULOE	
Type of Filing:		×	New Filing		☐ Amendmen	nt	
	A. I	BASIC II	ENTIFICATION D	ATA			
1. Enter the information requested abo	ut the issuer						
Name of Issuer (check if this is an am	endment and name has chan	ged, and i	ndicate change.)				
NeuroVentures Fund, LP						PROC	ESSEL
Address of Executive Offices	(Number ar	nd Street,	City, State, Zip Code) Telephone Num	ber (Including Area	a Code)	
c/o NeuroVentures Capital, LLC, Zero C	ourt Square, Charlottesville,	VA 2290	2	(804) 297-1000		1AN 2	1 2004
Address of Principal Business Operation (if different from Executive Offices)	s (Number and Street, City, S	State, Zip	Code)	Telephone Num	ber (Including Area	THO	MSON NCIAL
Brief Description of Business Venture capital investment							
Type of Business Organization							
☐ corporation	🗷 limited partnership, al	ready for	ned		☐ other (please	specify):	
☐ business trust	☐ limited partnership, to	be forme	d				
Actual or Estimated Date of Incorporatio	n or Organization:	-	Month 03	<u>Year</u> 2001	■ Actual	☐ Estimated	
Jurisdiction of Incorporation or Organiza	• • • • • •		Service abbreviation foreign jurisdiction)	for State: DE			

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.



- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
 - Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
 - Each general and managing partner of partnership issuers.

Check Box(es) that	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner
Apply:					
	t name first, if individual)				
NeuroVentures	Capital, LLC				
	idence Address (Number and	Street, City, State, Zip Code)			
Zero Court Squ	are, Charlottesville, VA 22902				
Check	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	▼ General and/or
Box(es) that					Managing Partner
Apply:		· · · · · · · · · · · · · · · · · · ·			7070000
	name first, if individual)				
Daniel J. O'Cor					
	idence Address (Number and S				
	are, Charlottesville, VA 22902				
Check Boxes that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	Managing Member of
			,		General Partner
	t name first, if individual)				
Mark A. Cochra					
	idence Address (Number and S				
	are, Charlottesville, VA 22902				
Check Boxes	☐ Promoter	Beneficial Owner	☐ Executive Officer	☐ Director	☐ Managing Member of
that Apply:					General Partner
•	t name first, if individual)				
James B. Murra					
	idence Address (Number and S				
	are, Charlottesville, VA 22902				
Check Boxes	☐ Promoter	Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or
that Apply:					Managing Partner
	t name first, if individual)				
RDP Investmen					
	idence Address (Number and Size, New York, NY 10017	street, City, State, Zip Code)			
	<u>-</u>			P=1 .	
Check Boxes that Apply:	☐ Promoter	🗷 Beneficial Owner	☐ Executive Officer	☐ Director	General and/or
					Managing Partner
-	t name first, if individual)				
NeuroVentures		7 0: 0 7. 0.1			
	idence Address (Number and Sare, Charlottesville, VA 22902				
Check Boxes					
that Apply:	☐ Promoter	Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or
					Managing Partner
Oak Neuro Part	t name first, if individual)				
		3: 6': 6: 5': 6 1)			
	sidence Address (Number and S				
	Street, Charlottesville, VA 229				
Check Box(es) that	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	General and/or
Apply:					Managing Partner
	t name first, if individual)				<u>,</u>
. un ranne (Las	i name moi, n marviduarj				
Business or Res	sidence Address (Number and	Street City State 7 in Code)			
200000 01 1000	(i anii anii anii anii anii anii anii				

					B.	INFORMA	TION ABO	OUT OFFEI	RING				
1.	Has the issu	er so ld, or do	es the issuer	intend to se					under ULOE.		У	'es No	<u>x</u>
2.	2. What is the minimum investment that will be accepted from any individual?								\$ 100,000)			
3.	Does the off	ering permit	joint owners	hip of a sing	gle unit?					•••••	Y	/es <u>x</u> No	
4.	of purchaser SEC and/or	rs in connecti	on with sale or states, list t	s of securiti	ies in the o the broker	ffering. If a	person to b	e listed is an	associated pe	rson or agent	of a broker of	or dealer regi	for solicitation stered with the or dealer, you
N/z	4												
Full	Name (Last r	name first, if	individual)			-/							
Bus	iness or Resid	lence Addres	s (Number a	nd Street, C	ity, State, 2	Zip Code)							
Nar	ne of Associa	ted Broker or	Dealer								. ,		
	es in Which F		II 0 1: :-		. 6.11	<u> </u>							
	••												🗆 All States
[AL		[AK]	[AZ]	[AR]	[CA]	(CO)	ICTI	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	•	[IN]	[IA2]	[KS]	(KY)	[LA]	[ME]	[MD]	[DC]	[MI]	[MN]	[MS]	[MO]
[M]		[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI	•	ISCI	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]
	Name (Last i	<u> </u>		1)	[171]	[0.1]	1, 1	[, , , ,]	[[[]	1,,,,,	[, , +]	[,,, 1]	[3.40]
Bus	iness or Resid	dence Addres	s (Number a	nd Street, C	ity, State, 2	Zip Code)							
Nar	ne of Associa	ted Broker or	Dealer								**********		
Stat	es in Which F	Person Listed	Has Solicite	d or Intend	s to Solicit	Purchasers							
(Ch	eck "All State	es" or check i	ndividual St	ates)		***************************************				•••••••••••	***************************************		🗆 All States
[AI	-}	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]		[IN]	[IA]	(KS)	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[M	רן	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI	l	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]
Ful	Name (Last	name first, if	individual)										
Bus	iness or Resid	dence Addres	s (Number a	nd Street, C	City, State, I	Zip Code)				***************************************			
Nai	ne of Associa	ted Broker or	Dealer										****
Cen	tes in Which T	Darcon I lotal	Has Calisies	od or Intand	e to Saliair	Durchasara							
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)													
(CI		[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	(HI)	[ID]
[IL		[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[M		[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI		[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already transaction is an exchange offering, check this box \(\Pi\) and indicate in the columns below the amounts of the			
	Type of Security	Aggregate		Amount Already
	•	Offering Price		Sold
	Debt	\$ 0		\$ 0
	Equity	\$ 0		\$ 0
	Common Preferred			
	Convertible Securities (including warrants)	\$ 0		\$ 0
	Partnership Interests	\$20,000,000		\$15,015,000
	Other (Specify)	\$ 0		\$ <u>15,015,000</u>
	Total	\$ 20,000,000		\$15,015,000
	Answer also in Appendix, Column 3, if filing under ULOE.	\$ 20,000,000		\$ <u>13,013,000</u>
2.				
۷.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."			
		Number		Aggregate
		Investors		Dollar Amount
				of Purchases
	Accredited Investors	22		\$ <u>15,015,000</u>
	Non-accredited Investors	0		\$ <u>0</u>
	Total (for filings under Rule 504 only)			\$
	Answer also in Appendix, Column 4, if filing under ULOE.			
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.			
		Type of		Dollar Amount
		Security		Sold
	Type of Offering			
	Rule 505			\$
	Regulation A			\$
	Rule 504			\$
	Total			\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.			
	Transfer Agent's Fees			\$
	Printing and Engraving Costs			\$
	Legal Fees		Ø	\$
	Accounting Fees			\$
	Engineering Fees			\$
	Sales Commissions (specify finders' fees separately)			\$
	Other Expenses (Identify) blue sky filing fees		X	\$1,300
	Total		×	\$ 20,000
	10(2)		6	٥

b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer". 5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Payment to Officers, Payment to Officers, Directors, & Affiliates Others Salaries and fees (over a ten-year period). Purchase, renal or leasing and installation of machinery and equipment. Purchase, renal or leasing of plant buildings and facilities. Construction or leasing of plant buildings and facilities in exchange for the assets or securities involved in this offering that may be used so the section of securities of another issuer pursuant to a merger). Repayment of indebtedness Working capital. Other (specify): D. FEDERAL SIGNATURE The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filled under Rule 505, the following signature constitutes an undertaking by the issuer to farmish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Signature Date NeuroVentures Fund, LP Name of Signer (Print or Type) By Paymel, Commell	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND	USE OF PROCEEDS	
If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4 be above. Payment to Officers, Directors, & Affiliates Salaries and fees (over a ten-year period)			\$ <u>19.978,700</u>
Salaries and fees (over a ten-year period)	If the amount for any purpose is not known, furnish an estimate and check the box to the left of the	estimate. The total of the on 4.b above.	
Purchase of real estate		•	•
Purchase, rental or leasing and installation of machinery and equipment	Salaries and fees (over a ten-year period)	× \$4,000,000	□ \$
Construction or leasing of plant buildings and facilities	Purchase of real estate	□ \$	□ s
Construction or leasing of plant buildings and facilities	Purchase, rental or leasing and installation of machinery and equipment	□ s	□ s
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) Repayment of indebtedness Working capital Other (specify): S S S S S S S S S S S S S Column Totals Total Payments Listed (column totals added) D. FEDERAL SIGNATURE The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Neuro Ventures Fund, LP Name of Signer (Print or Type) By Neuro Ventures Capital, LLC, its general partner	Construction or leasing of plant buildings and facilities		
Working capital			□ s
Other (specify): Other (specify): S S S S S S S Column Totals Column Totals D. FEDERAL SIGNATURE The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Name of Signer (Print or Type) By Neuro Ventures Capital, LLC, its general partner	Repayment of indebtedness	\$	□ s
Column Totals State (column totals added) State (column to	Working capital	□ \$	
Column Totals Sq. Sq.000,000 Ex s 15,978,700 Total Payments Listed (column totals added) D. FEDERAL SIGNATURE The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Name of Signer (Print or Type) Name of Signer (Print or Type) Name of Signer (Print or Type) Neuro Ventures Capital, LLC, its general partner	Other (specify):	Пс	
Column Totals			
D. FEDERAL SIGNATURE The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Neuro Ventures Fund, LP Name of Signer (Print or Type) By Neuro Ventures Capital, LLC, its general partner			
D. FEDERAL SIGNATURE The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Neuro Ventures Fund, LP Name of Signer (Print or Type) By Neuro Ventures Capital, LLC, its general partner			
The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) NeuroVentures Fund, LP Name of Signer (Print or Type) By NeuroVentures Capital, LLC, its general partner	Total 1 dylinents Listed (column totals added)	\(\begin{align*} \begin{align*} \be	700
The issuer had duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) NeuroVentures Fund, LP Name of Signer (Print or Type) By NeuroVentures Capital, LLC, its general partner			
an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) NeuroVentures Fund, LP Name of Signer (Print or Type) By NeuroVentures Capital, LLC, its general partner	D. FEDERAL SIGNATURE		
NeuroVentures Fund, LP Name of Signer (Print or Type) By NeuroVentures Capital, LLC, its general partner NeuroVentures Fund, LP Sitle of Signer (Print or Type)	an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request	is filed under Rule 505, the of its staff, the information	following signature constitutes a furnished by the issuer to any
Name of Signer (Print or Type) By NeuroVentures Capital, LLC, its general partner	1 - OH O		Date
By NeuroVentures Capital, LLC, its general partner			

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

	E. STATE SIGNATURE						
1.	Is any party described in 17 CFR 230.252 presently subject to any of the disqualification provisions of such rule?	Yes	No 🗷				
	See Appendix, Column 5, for state response.						
2.	The undersigned issuer hereby undertakes to furnish to the state administrator of any state in which the notice is filed, a notice on Form D (17 times as required by state law.	CFR 239.50	00) at such				
3.	The undersigned issuer hereby undertakes to furnish to any state administrators, upon written request, information furnished by the issuer to of	ferees.					
4.	The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.						
The	e issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the under	signed duly	authorized				
pers	rson,						
Issu	uer (Print or Type)	Date					
Neuro Ventures Fund, LP							
Nar	Name (Print or Type) Type Type						
Ву	By Neuro Ventures Capital, LLC, its general partner						
By Daniel J. O'Connell Managing Director							

Instruction:
Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. At copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.